Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Methylphenidate · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Methylphenidate hydrochloride | DRUG | - |
Inclusion Criteria: Patients who meet all of the following inclusion criteria will be eligible for enrollment in the study: * Male and female patients aged 6-14. * Patients having a diagnosis of ADHD of any type according to DSM-IV criteria, as established by history, psychiatric examination and a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 1 | PHASE3 | SPN-812 |
Methylphenidate is a small molecule used for the treatment of attention deficit hyperactivity disorder (ADHD) in children. It is being developed by Novartis AG as a modified-release oral dosage form. The drug is currently in Phase 3 clinical development for this indication.
Methylphenidate is being developed by Novartis AG, a pharmaceutical company listed on the stock exchange under the ticker NVS. The drug is in Phase 3 clinical development for the treatment of ADHD in children aged 6 to 14 years.
Methylphenidate is in Phase 3 clinical development. A Phase 3 trial has been completed for the drug in children with ADHD. The drug is investigational and has not been approved for use.
Methylphenidate has one completed Phase 3 clinical trial, identified as NCT00254878. This trial was a placebo-controlled comparison of two different brands of modified-release oral dosage forms in children with ADHD aged 6 to 14 years. The trial enrolled 130 participants and was conducted in Germany.
Methylphenidate is being studied as a modified-release oral dosage form. The completed Phase 3 trial compared two different brands of modified-release oral dosage forms of the drug. The trial was double-blind and randomized, though it did not use a control group.